The study by Oxford University investigated the ability of monoclonal antibodies in Sera from recovered people and from vaccinated people to neutralize the Delta and Kappa variants, the statement said.
An upcoming study by Oxford University showed that a third dose of the vaccine boosted antibodies to the coronavirus spike protein among participants, it added.
The trial results, primarily generated in the United States but also in Chile and Peru, included a 79% efficacy in preventing symptomatic COVID-19, and showed no increased risk of a rare form of blood clots that has caused concern in parts of Europe.
Britain's Medicines and Healthcare products Regulatory Agency concluded at the time that a 12-week gap between doses was the key to achieving the highest efficacy, of around 80%.
The suspensions have provoked intense debate over whether it was prudent to put AstraZeneca inoculations on hold just as vaccination campaigns were beginning to gather pace.
Yousafzai was awarded the Nobel Peace Prize as a 17-year-old in 2014, sharing the award with Kailash Satyarthi, a children's rights activist from India.
Britain has been rolling out the shot among all age groups after the Medicines and Healthcare products Regulatory Agency (MHRA) was the first regulator to approve it in December.
Nevertheless, there was no evidence there, suggesting that those people over 65 were not getting evidence of efficacy.
Indian health officials say they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in its citizens whose genetic makeup can be different from people in Western nations.
The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people.
The EMA has actually not restricted this vaccine in terms of age based upon the entire data packages, and of course that is a stringent regulatory authority.